US Patent

US11389510 — Controlled-release CNP agonists with low initial NPR-B activity

Composition of Matter · Assigned to Ascendis Pharma Growth Disorders AS · Expires 2037-01-05 · 11y remaining

Vulnerability score 17/100 Ironclad — strong claim type, well-established, deep family

What this patent protects

This patent protects a controlled-release version of a CNP agonist with specific properties, including a release half-life of at least 6 hours and certain EC50 values.

USPTO Abstract

The present invention relates to a controlled-release CNP agonist from which CNP agonist is released with a release half-life of at least 6 hours under physiological conditions and which controlled-release CNP agonist has an EC50 that is at least 20-fold higher than the EC50 of the corresponding free CNP agonist and which released CNP agonist has an EC50 that is at most 3-fold higher than the EC50 of the corresponding free CNP agonist; to pharmaceutical compositions comprising said controlled-release CNP agonist; their use; and to methods of treatment.

Drugs covered by this patent

Patent Metadata

Patent number
US11389510
Jurisdiction
US
Classification
Composition of Matter
Expires
2037-01-05
Drug substance claim
Yes
Drug product claim
Yes
Assignee
Ascendis Pharma Growth Disorders AS
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.